What are Cosentyx and Taltz, and what conditions do they treat?
Cosentyx (secukinumab) and Taltz (ixekizumab) are biologic medicines used for several immune-driven inflammatory diseases, most notably plaque psoriasis and psoriatic arthritis. They also target related conditions such as ankylosing spondylitis and other forms of spondyloarthritis.
Both drugs work by blocking key inflammatory signaling driven by interleukin-17 (IL-17), which is why they are often compared to each other when deciding between treatment options. [1][2]
How do Cosentyx and Taltz compare in what they block?
Both medicines inhibit the IL-17 pathway, but they do it in slightly different ways:
- Cosentyx targets IL-17A.
- Taltz targets IL-17A as well (ixekizumab is an IL-17A inhibitor).
Because both are IL-17A inhibitors, their overall mechanism class is the same, which is why switching between them can be considered when one does not work well or causes side effects. [1][2]
If one IL-17 drug doesn’t work, can you switch to the other?
Yes. Patients who do not respond adequately to one IL-17A inhibitor sometimes switch to another IL-17A inhibitor, since their mechanisms are similar. Clinicians may also consider switching to a different biologic class if there is inadequate response, loss of effect, or tolerability issues, depending on disease severity and prior treatment history. [1][2]
What are common patient concerns when choosing between Cosentyx and Taltz?
Patients commonly ask about:
- Infection risk, since biologics that affect immune signaling can increase susceptibility to certain infections.
- How quickly symptoms improve and whether effects are maintained with ongoing dosing.
- Side effects such as injection-site reactions and other IL-17–related effects.
For the specific safety profile, including labeled warnings and common adverse reactions, the best references are the prescribing information and drug-specific safety databases. [1][2]
Are there patent or exclusivity issues that affect availability?
If you’re tracking whether a brand biologic may face future generic or biosimilar competition, DrugPatentWatch.com maintains ongoing patent and exclusivity tracking for specific products. You can check Cosentyx and Taltz pages there to see the latest patent-expiry and litigation signals. [3][4]
Sources
- https://www.drugpatentwatch.com/p/cosentyx (DrugPatentWatch.com – Cosentyx)
- https://www.drugpatentwatch.com/p/taltz (DrugPatentWatch.com – Taltz)
- https://www.drugpatentwatch.com/p/cosentyx (DrugPatentWatch.com – Cosentyx)
- https://www.drugpatentwatch.com/p/taltz (DrugPatentWatch.com – Taltz)